Peptide Protocol

App Store

BPC-157 dosing windows: does plasma half-life matter?

BPC-157's pharmacokinetics in humans are sparse, but available data suggest a plasma half-life of roughly 30 minutes after subq injection. The biological effect appears to outlast plasma presence by hours or days. This gap is why dosing frequency recommendations vary wildly — twice daily, once daily, every other day all have proponents.

What the half-life literature shows

Available rodent studies and limited human data suggest BPC-157 has:

• Plasma half-life ~30 minutes after subq injection.
• Tissue half-life longer — radiolabeled peptide is detected in tissues for 24+ hours.
• Bioavailability ~95–100% from subq injection.
• Some persistent tissue effects for days after a single dose in injury models.

The numbers come mostly from rodent pharmacokinetics; human data is much sparser. Treat the 30-minute plasma half-life as an estimate, not a precise number.

The plasma-vs-tissue gap

Many drugs have plasma half-lives that don't reflect their biological duration of action. Steroids, anti-inflammatories, and some peptides all show "tissue persistence" effects where the molecule is taken up by target cells, internalized, and continues signaling even after blood levels drop.

For BPC-157, three plausible mechanisms could explain why the effect outlasts plasma presence:

1. Cellular uptake. BPC-157 may be internalized by target cells and produce sustained intracellular signaling.
2. Receptor or pathway activation cascades. The peptide may trigger downstream changes (gene expression, growth factor release) that outlast its presence.
3. Slow elimination from connective tissue. The peptide may diffuse into and out of tissue compartments slowly, with the plasma half-life reflecting only the central compartment.

What this means for dosing frequency

Once daily

The most commonly used regimen. Sufficient for systemic tissue effects in most reports. If the tissue effect persists for 24+ hours, once-daily covers the daily window.

Twice daily

Often suggested for acute injury phases. The rationale is that early in healing, more frequent stimulation may enhance tissue response. Whether twice-daily produces better results than once-daily in humans is unverified; rodent data is mixed.

Every other day

Less common. May be reasonable for maintenance phases or for users who tolerate fewer injections. Theoretical risk that gaps allow tissue effect to fully fade between doses.

Pulse cycling (4 weeks on, 2 weeks off)

Cycling is recommended by some practitioners to reduce cumulative exposure and potentially limit immunogenicity (see FDA warnings on immunogenicity). Whether cycling preserves efficacy or simply reduces it is unclear.

The "plasma half-life doesn't matter" view

Some practitioners argue that BPC-157's plasma half-life is essentially irrelevant — the drug works through tissue effects that persist days, and the plasma is just the delivery mechanism. Under this view, dose frequency is set by practical considerations (daily injection burden, tissue saturation) rather than pharmacokinetic ones.

The counter-view

Other practitioners argue that the short plasma half-life means you can only deliver biologically active concentrations for a limited window per dose. Twice-daily then makes sense to maintain those windows. Under this view, dosing protocols circulated online with once-weekly BPC-157 (sometimes seen) are likely too sparse to have effect.

What the user-reported data suggests

Anecdotal user reports (acknowledging the low evidence quality) suggest:

• Once-daily protocols produce clinically reported effects (perceived healing, reduced inflammation) similar to twice-daily.
• Twice-daily during acute injury may produce faster initial response.
• Every-other-day or longer gaps are associated with weaker reported effects.
• Long-term continuous use (3+ months) often correlates with reduced perceived effect — possibly immune tolerance, possibly placebo decay.

Local vs systemic targeting

Injection site choice can also affect what BPC-157 reaches:

• Subq abdomen: systemic distribution, distant tissue effects.
• Subq near target tissue (e.g., near an injured tendon): higher local concentration at the target. Some practitioners do this; the evidence is weak.
• Oral: mostly local-GI effects. See BPC-157 oral vs injectable.
• Sublingual: partial systemic; some debate over benefits over swallowed oral.

Practical takeaways

1. Once-daily is the default reasonable starting point for most users.
2. Twice-daily during acute injury is a reasonable but unverified addition.
3. Total daily dose (250–500 mcg) appears more important than split timing.
4. 4–6 week cycles with breaks may be wiser than continuous long-term use.
5. Track effect over time — log subjective response. Loss of effect after 2–3 months suggests stopping rather than dose-escalating.

FAQ

Related reading

Informational and educational only. Not medical advice. Consult a licensed clinician before starting, changing, or stopping any peptide protocol. Mentions of investigational, compounded, or research-use peptides are for informational purposes; many such substances are not FDA-approved for human use.